Navigation Links
BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
Date:9/4/2008

in the United

States.

- MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)

patients in Europe.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but a
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. BioMS Medical Announces Second Quarter 2008 Results
4. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
5. BioMS Medical to present at BMO Healthcare Conference
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical to present at Jefferies Healthcare Conference
8. BioMS Medical to present at 2008 BIO International Convention
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical announces first quarter 2008 results
11. BioMs Medical to present at TIDES(R) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
(Date:8/19/2014)... Scottsdale, AZ (PRWEB) August 19, 2014 ... the launch of its online sales skills training ... their sales skills. , MedTech clinical staff spend the ... at a hospital, standalone medical center, or physician practice ... administrative staff. But why stop there? Sales Horizons believes ...
(Date:8/18/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a life ... products for advanced microarray diagnostics, today announced it will ... at 2:00 pm ET.  During the ... brief review of SQI,s recent commercialization progress and then ... veteran recently appointed to the Board of Directors of ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3
... Sept. 15 Epeius Biotechnologies,Corporation today announced that ... has been highlighted in a recent NEWS article,published ... (JNCI, Sept. 9,2008). The article, authored by Vickie ... medicine that may succeed where small,molecules and proteins ...
... Enobia Pharma, an emerging biotech,company focused ... presented pre-clinical data demonstrating that its enzyme,replacement ... bones that,have already been severely weakened by ... with Enobia,s product ENB-0040, significantly,increases survival and ...
... Offers Industry Dialogue, Commentary and How-To, ... Collaboration, PALO ALTO, Calif., Sept. 15 ... strategist and communicator, has,launched a new website, ... and communicators can share thinking, gain insights and,connect ...
Cached Biology Technology:Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal 2Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice 2Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice 3
(Date:8/20/2014)... Multiple fires are visible in in this image of ... Many of these were most likely intentionally set in ... of a forest or stand of trees where the ... of deforestation include conversion of forestland to farms, ranches, ... the dark green of the Amazon Rainforest in the ...
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... found that new disease pathways involving more than one ... rare genetic disorder in which fatty substances called glycosphingolipids ... pain, and increased risk of cancer and Parkinson,s disease. ... expensive and more effective ways to treat the disorder, ...
... release is available in French . , Scientists ... McGill University have discovered that our brains have the ability ... specially-coded sounds, without any visual or tactile input. Not only ... the brain and how it perceives the world around us, ...
... Inhaling nitric oxide appears to safely and effectively ... researchers report., A study of 18 patients in Atlanta, ... oxide for four hours had better pain control than ... C. Alvin Head, chairman of the Department of Anesthesiology ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2See no shape, touch no shape, hear a shape? 2Inhaling nitric oxide eases pain crises in sickle cell patients 2
... 94kDa ultra-pure recombinant thermostable DNA polymerase obtained ... DNA polymerase gene in E. coli, Concentration: ... of Thermo Fisher Scientific, the world leader ... customers to make the world healthier, cleaner ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
Biology Products: